[Synthetic depot-ACTH, plasmacortisol levels, and asthmatic syndrome (author's transl)].
Plasmacortisol levels were measured in 33 patients with asthmatic syndrome before and after they received treatment with 6 mg of depot-ACTH (Tetracosactid) over seven days. 75 percent of the patients showed improved VC and FEF after therapy. This effect was not in any way correlated to the basal level of cortisol, nor to the increment during treatment.
D000324:Adrenocorticotropic Hormone / Q000009:adverse effects / Q000138:chemical synthesis / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D001249:Asthma / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D003692:Delayed-Action Preparations; D004351:Drug Resistance; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011654:Pulmonary Edema / Q000139:chemically induced; D012123:Pulmonary Ventilation; D014797:Vital Capacity
D003692:Delayed-Action Preparations; D000324:Adrenocorticotropic Hormone; D006854:Hydrocortisone
Synthetisches Depot-ACTH, Plasmacortisol und Asthma bronchiale